Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5953470 | 0.99 | SOAT1 (0.99) | ACAT1SOAT1 | |
| Hydrochloric Acid SCHEMBL5953844 | 0.99 | SOAT1 (1.00) | ACAT1SOAT1 | |
| SCHEMBL6635258 | 0.94 | ACAT1 (0.89) | ACAT1SOAT1 | |
| SCHEMBL31061433 | 0.94 | ACAT1 (0.88) | ACAT1SOAT1 | |
| SCHEMBL7615047 | 0.92 | ACAT1 (0.85) | ACAT1SOAT1 | |
| SCHEMBL6639853 | 0.92 | ACAT1 (0.85) | ACAT1SOAT1 | |
| SCHEMBL7615339 | 0.90 | ACAT1 (0.81) | ACAT1SOAT1 | |
| SCHEMBL8327206 | 0.90 | ACAT1 (0.81) | ACAT1SOAT1 | |
| SCHEMBL6632704 | 0.89 | ACAT1 (0.80) | ACAT1SOAT1 | |
| SCHEMBL8324521 | 0.89 | ACAT1 (0.80) | ACAT1SOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 344 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192220-A1 | TREATMENT FOR SOLID TUMORS | ORE PHARMACEUTICALS INC. (US) | 2009-07-30 | — | — | US | claimed |
| US-20070099891-A1 | Medicinal compositions and combinations | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-05-03 | — | — | US | claimed |
| EP-1695706-A1 | MEDICINAL COMPOSITIONS AND COMBINATIONS | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-08-30 | — | — | EP | claimed |
| US-6420381-B1 | ACYL-COA: CHOLESTEROL ACYL TRANSFERASE (ACAT) INHIBITORY ACTIVITY, AND IS USEFUL AS AN AGENT FOR TREATMENT OF HYPERLIPIDEMIA AND ATHEROSCLEROSIS. | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-07-16 | — | — | US | claimed |
| CN-116710439-B | Substituted pyrazolopiperidine carboxylic acids | BAYER AG (DE) | 2026-05-26 | — | — | CN | disclosed |
| EP-4744669-A2 | APOLIPOPROTEIN C3 (APOC3) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| CN-116829545-B | Substituted pyrazolylpiperidine carboxylic acids | 拜耳公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12595247-B2 | Substituted pyrazolo piperidine carboxylic acids | BAYER AKTIENGESELLSCHAFT (DE) | 2026-04-07 | — | — | US | disclosed |
| US-12540134-B2 | Inhibitors of adrenoreceptor ADRAC2 | BAYER AKTIENGESELLSCHAFT (DE) | 2026-02-03 | — | — | US | disclosed |
| US-12522822-B2 | Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-12503469-B2 | Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate | ADVERIO PHARMA GMBH (DE) | 2025-12-23 | — | — | US | disclosed |
| US-20250361282-A1 | ATRIAL NATRIURETIC PEPTIDE ENGRAFTED ANTIBODIES | BAYER AKTIENGESELLSCHAFT (DE) | 2025-11-27 | — | — | US | disclosed |
| WO-2008017381-A1 | ARYLAMINOARYL-ALKYL-SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, PROCESSES FOR PREPARING THEM, MEDICAMENTS COMPRISING THESE COMPOUNDS, AND THEIR USE | SANOFI-AVENTIS (FR) | 2008-02-14 | — | — | WO | disclosed |
| US-20070099891-A1 | Medicinal compositions and combinations | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-05-03 | — | — | US | disclosed |
| EP-1695706-A1 | MEDICINAL COMPOSITIONS AND COMBINATIONS | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-08-30 | — | — | EP | disclosed |
| JP-2006063066-A | MEDICINAL COMPOSITION HAVING ANTI-ARTERIOSCLEROTIC ACTION | SANKYO CO LTD | 2006-03-09 | — | — | JP | disclosed |
| WO-2006011551-A1 | PHARMACEUTICAL COMPOSITION HAVING ANTI-ARTERIOSCLEROSIS POTENCY | SANKYO COMPANY LIMITED (JP) | 2006-02-02 | — | — | WO | disclosed |
| EP-1420017-A1 | 1,2-DIHYDRO-2-OXO-1,8-NAPHTHYRIDINE DERIVATIVE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-05-19 | — | — | EP | disclosed |
| US-6420381-B1 | ACYL-COA: CHOLESTEROL ACYL TRANSFERASE (ACAT) INHIBITORY ACTIVITY, AND IS USEFUL AS AN AGENT FOR TREATMENT OF HYPERLIPIDEMIA AND ATHEROSCLEROSIS. | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-07-16 | — | — | US | disclosed |
| EP-1104763-A1 | NAPHTHYRIDINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2001-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503469-B2 | Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate | KDM2B, KDM6B, KDM3B | ACAT1 3260/4885SOAT1 4466/4885 |
| US-12540134-B2 | Inhibitors of adrenoreceptor ADRAC2 | ADRA2C, ADRB3, ADRB2 | ACAT1 997/4885SOAT1 1453/4885 |
| US-20090192220-A1 | TREATMENT FOR SOLID TUMORS | ACAT2, ACAT1, APRT | ACAT1 2/4885SOAT1 65/4885 |
| US-12595247-B2 | Substituted pyrazolo piperidine carboxylic acids | SSB, PDK4, FPR1 | ACAT1 2964/4885SOAT1 3211/4885 |
| US-20070099891-A1 | Medicinal compositions and combinations | HMGCR, APOB, CYP46A1 | ACAT1 69/4885SOAT1 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.